23938-73-0

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-3-methoxy-4-(phenylmethoxy)benzoic acid is used as a histone deacetylase inhibitor for its ability to modify chromatin structure and alter gene expression. This makes it a potential therapeutic agent for the treatment of various cancers and diseases related to epigenetic dysregulation.
Used in Oncology:
Mocetinostat is utilized as an anticancer agent, targeting the epigenetic mechanisms that contribute to the development and progression of malignancies. Its histone deacetylase inhibitory activity can potentially lead to the reversion of cancerous cells to a more normal state, thereby offering a novel approach to cancer treatment.
Used in Neurodegenerative Disease Research:
2-Amino-3-methoxy-4-(phenylmethoxy)benzoic acid is being studied for its potential in the treatment of neurodegenerative diseases. Given its influence on gene expression and chromatin structure, it may offer new avenues for managing or treating conditions such as Alzheimer's disease, Parkinson's disease, and other related disorders where epigenetic factors play a role.

Upstream product

• 3584-32-5 4-(benzyloxy)-3-methoxy-2-nitrobenzoic acid 

Downstream Products

• 1325207-76-8 (E)-3-(6-benzyloxy-1,2,3,5-tetramethoxy-9-oxo-9H-acridin-10-yl)acrylic acid 
• 1325207-46-2 (E)-3-(6-benzyloxy-1,2,3,5-tetramethoxy-9-oxo-9H-acridin-10-yl)acrylic acid 
• 1325207-42-8 6-benzyloxy-1,2,3,5-tetramethoxy-10H-acridin-9-one 
• 1325207-40-6 4-benzyloxy-3-methoxy-2-(3,4,5-trimethoxyphenylamino)benzoic acid 
• 1325207-38-2 4-benzyloxy-2-iodo-3-methoxybenzoic acid 
• 142003-90-5 3-(benzyloxy)-5-methyl-4,6,7-trimethoxyquino<3,2-a>phenazin-14(5H)-one 
• 142003-86-9 6-(benzyloxy)-10-<2-(diethylamino)ethyl>-1,2,3,4,5-pentamethoxyacridin-9-one 
• 142003-88-1 6-(benzyloxy)-2,3-dimethoxy-10-methylacridine-1,4,9-trione 
• 142003-89-2 6-(benzyloxy)-3,4-dimethoxy-10-methylacridine-1,2,9-trione 
• 135082-46-1 6-(benzyloxy)-10-methyl-1,2,3,4,5-pentamethoxyacridin-9-one 
• 135082-45-0 6-(benzyloxy)-1,2,3,4,5-pentamethoxyacridin-9-one 
• 135082-47-2 6-(benzyloxy)-1-hydroxy-10-methyl-2,3,4,5-tetramethoxyacridin-9-one 
• 82354-35-6 des-N-methylnoracronycine 
• 135082-42-7 4-(benzyloxy)-3-methoxy-N-(2,3,4,5-tetramethoxyphenyl)anthranilic acid 

Relevant academic research and scientific papers

Multisubstituted 1-hydroxy-9-acridones with anticancer activity

The present invention provides a compound having the structure: STR1 The present invention also provides a method for synthesizing a compound having the above-identified structure as well as the intermediate compounds produced according to that method. The present invention further provides a pharmaceutical composition comprising the above compounds. Lastly, the present invention provides a method of inhibiting growth of tumor cells.

Synthesis of the acridone alkaloids glyfoline and congeners. Structure- activity relationship studies of cytotoxic acridones

Glyfoline (4, 1,6-dihydroxy-10-methyl-2,3,4,5-tetramethoxyacridin-9-one) and its congeners were synthesized for evaluation of their cytotoxicity. A detailed structure-activity relationships (SAR) of these acridone derivatives were also studied. To study t

SYNTHESIS OF GLYFOLINE, A CONSTITUENT OF GLYCOSMIS CITRIFOLIA (WILLD.) LINDL. AND A POTENTIAL ANTICANCER AGENT

Condensation of 4-benzyloxy-3-methoxyanthranilic acid (3) with 5-iodo-1,2,3,4-tetramethoxybenzene (4) gave 6-benzyloxy-1,2,3,4,5-pentamethoxy-9-acridone (7), which was then converted into glyfoline (1) via N-methylation, selective de-O-methylation, and de